GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
0.609
-0.020 (-3.24%)
At close: Dec 5, 2025, 4:00 PM EST
0.603
-0.006 (-1.05%)
After-hours: Dec 5, 2025, 7:03 PM EST
GT Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
6.48M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GTBP News
- 16 days ago - GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials - Accesswire
- 21 days ago - GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - GT Biopharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 - GlobeNewsWire
- 6 months ago - GT Biopharma Appoints New Member to its Board of Directors - GlobeNewsWire
- 7 months ago - GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals - GlobeNewsWire
- 10 months ago - GT Biopharma Announces Exercise of Warrants - GlobeNewsWire
- 1 year ago - GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewsWire